The present invention is related to benzimidazole acetonitriles as well as
to pharmaceutical formulations containing such benzimidazole
acetonitriles of formula (I). Said benzimidazole acetonitriles are useful
in the treatment of metabolic disorders mediated by insulin resistance or
hyperglycemia, comprising diabetes type II, inadequate glucose tolerance,
insulin resistance, obesity, polycystic ovary syndrome (PCOS) (I). The
present invention is furthermore related to methods of preparing
benzoxazole acetonitriles. G is pyrimidinyl; L is an amino group, or a
3-8 membered heterocycloalkyl, containing at least one heteroatom
selected from N, O, S or L is an acylamino moiety; R.sup.1 is selected
from the group comprising or consisting of hydrogen, sulfonyl, amino,
carboxy, aminocarbonyl, C.sub.1-C.sub.6-alkyl, C.sub.2-C.sub.6-alkenyl,
C.sub.2-C.sub.6-alkynyl or C.sub.1-C.sub.6-alkoxy, aryl, halogen, cyano
or hydroxy; R.sup.2 is selected from the group comprising or consisting
of hydrogen, C.sub.1-C.sub.6-alkyl, C.sub.2-C.sub.6alkenyl,
C.sub.2-C.sub.6-alkynyl, or C.sub.1-C.sub.6-alkoxy.